NEW YORK, Feb. 13, 2015 /PRNewswire/ -- Vaccines are a big business, and a growing business, says healthcare market researcher Kalorama Information but the industry has unique circumstances and challenges. The healthcare market researcher estimated the market for revenues earned by manufacturers of vaccines was 25.5 billion dollars in 2014 with influenza and pneumococcal among the largest categories in terms of revenue. Kalorama has estimated markets for vaccine products for decades, and says the market is relatively small compared to the overall pharmaceutical market, and production costs and discounts are challenges in the industry. Its current report on the vaccine industry is Vaccines 2014.
The report is available at Kalorama Information at: http://www.kaloramainformation.com/Vaccines-Key-Players-8120410/.
"It is a lower profit business than traditional pharmaceuticals unless we are talking about novel vaccines or delivery forms," said Bruce Carlson, publisher of Kalorama Information. "On the other hand, the companies that are now in the vaccines marketplace have been in the market a long time. It can be more dependable revenue with a small customer base and normally less sales expense."
Top vaccine companies Merck, Sanofi Aventis, Pfizer, Glaxo and Novartis controlled 88% of the market in 2014 according to Kalorama Information. Last year, Novartis decided to sell its vaccine business to Australia-based CSL. Novartis left in order to pursue cancer drugs and other categories.
Kalorama notes that vaccine revenues do not reflect profits to the companies and that while profits can be difficult to calculate, they are lower than traditional pharmaceutical products. Kalorama says that vaccines are expensive to make, in-house facilities are expensive and outside suppliers such as egg farms and contract biomanufacturers can often be at capacity in peak seasons. Since the largest payers are governments with high volume negotiating power, discounts are a part of the business. Still, Kalorama says, companies in vaccines want the dependable revenue lines and presence in the traditional vaccine markets give them possible entre when they launch a novel vaccine product or vaccine mechanism from their pipelines.
Kalorama Information's report, Vaccine 2014 breaks out revenues for every major category of vaccines and projects them to 2020. The report profiles major companies in the market and smaller innovators, and discusses important trends. The report can be found at: http://www.kaloramainformation.com/Vaccines-Key-Players-8120410/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
SOURCE Kalorama Information